Login / Signup

Efficacy and safety of canakinumab in systemic juvenile idiopathic arthritis, the first Chinese experience.

Lingzhi QiuLe MaYifan XieJing JinYuting PanShumin LiZhidan FanHai-Guo Yu
Published in: Pediatric rheumatology online journal (2024)
Canakinumab was found to be potentially efficacious and safe in Chinese patients with sJIA. No new AEs were observed with canakinumab treatment.
Keyphrases
  • juvenile idiopathic arthritis
  • disease activity
  • rheumatoid arthritis
  • systemic lupus erythematosus
  • combination therapy
  • replacement therapy